{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:08Z","timestamp":1787169728034,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim of the study is to report a case of corneal epithelial changes in a patient with refractory multiple myeloma (MM) who was treated with belantamab mafodotin (BM). A 55-year-old man diagnosed with refractory MM was referred to our hospital for treatment with BM, an antibody-drug conjugate targeting B-cell maturation antigen. After 33 days of treatment, the patient experienced a bilateral reduction in visual acuity (VA), along with dry eye symptoms such as itchy eyes and a sensation of having a foreign body. Slit-lamp examination revealed the presence of diffuse microcystic epithelial changes throughout the cornea. BM treatment was discontinued by the oncologist. Sixty days after stopping belantamab, VA gradually improved and the microcystic epithelial alterations progressively diminished. Ninety days after discontinuation of therapy, only a few microcystic epithelial alterations remained, and the patient had 20\/20 VA in both eyes. While BM is an effective therapy for refractory MM, corneal epithelial changes are among the most common side effects of this treatment. Close collaboration between ophthalmologists and oncologists is crucial for assessing ocular adverse effects and tailoring treatment accordingly.<\/jats:p>","DOI":"10.4103\/tjo.tjo-d-22-00171","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T05:41:44Z","timestamp":1694065304000},"page":"380-383","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Corneal epithelial changes in a patient treated with belantamab mafodotin"],"prefix":"10.4103","volume":"13","author":[{"given":"Leandro","family":"Inferrera","sequence":"first","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, Eye Clinic, University of Trieste, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Giglio","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, Eye Clinic, University of Trieste, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Tognetto","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical Sciences and Health, Eye Clinic, University of Trieste, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma:ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival:A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clml.2016.11.010","article-title":"Practical considerations in managing relapsed multiple myeloma","volume":"17","author":"Agarwal","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma:A comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159):A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin:First approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma:An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13045-021-01172-5","article-title":"Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly:A case report","volume":"14","author":"Marquant","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","article-title":"Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma:A case series from the first-time-in-human clinical trial","volume":"105","author":"Popat","year":"2020","journal-title":"Haematologica"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2):A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"R16-20240830","first-page":"3","article-title":"Antibody-drug conjugates:Possibilities and challenges","volume":"11","author":"Nejadmoghaddam","year":"2019","journal-title":"Avicenna J Med Biotechnol"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/ICL.0000000000000768","article-title":"Corneal changes after belantamab mafodotin in multiple myeloma patients","volume":"47","author":"Bausell","year":"2021","journal-title":"Eye Contact Lens"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.3390\/jcm11102884","article-title":"Corneal findings associated to belantamab-mafodotin (belamaf) use in a series of patients examined longitudinally by means of advanced corneal imaging","volume":"11","author":"Mencucci","year":"2022","journal-title":"J Clin Med"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates:A meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Invest New Drugs"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-22-00171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:12:37Z","timestamp":1787166757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-22-00171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-22-00171","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2022-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}